Literature DB >> 32448557

A Perspective on Multi-target Drugs for Alzheimer's Disease.

Ondrej Benek1, Jan Korabecny2, Ondrej Soukup3.   

Abstract

Alzheimer's disease (AD) has a complex pathophysiology that includes aggregation of pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia-mediated neuroinflammation. Therapeutics targeting only one of these AD-related subpathologies have not yet been successful in the search for a disease-modifying treatment. Therefore, multi-target drugs (MTDs) aiming simultaneously at several subpathologies are expected to be a better approach. However, the concept of MTD is inherently connected with several limitations, which are often ignored during MTD design and development. Here, we provide an overview of the MTD approach and discuss its potential pitfalls in the context of AD treatment. We also put forward ideas to be used in the rational design of MTDs to obtain drugs that are effective against AD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; designed multiple ligands; drug design; multi-target drugs; polypharmacology

Year:  2020        PMID： 32448557     DOI： 10.1016/j.tips.2020.04.008

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  33 in total

1.  1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2, 3-Triazole-4- carboxamide Reduces Aβ Formation and Tau Phosphorylation in Cellular Models of Alzheimer's Disease.

Authors:  Mariana G Fronza; Manoela Sacramento; Diego Alves; Domenico Praticò; Lucielli Savegnago
Journal:  Neurochem Res       Date:  2022-02-15       Impact factor: 3.996

2.  Neuroprotective and Antioxidant Role of Oxotremorine-M, a Non-selective Muscarinic Acetylcholine Receptors Agonist, in a Cellular Model of Alzheimer Disease.

Authors:  Giuseppa Mudò; Valentina Di Liberto; Domenico Nuzzo; Monica Frinchi; Costanza Giardina; Miriana Scordino; Mariachiara Zuccarini; Chiara De Simone; Marta Di Carlo; Natale Belluardo
Journal:  Cell Mol Neurobiol       Date:  2022-09-03       Impact factor: 4.231

3.  A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer's Disease by Dual Inhibition of Acetylcholinesterase and Inflammation.

Authors:  Chan Liu; Zhipei Sang; Hong Pan; Qin Wu; Yu Qiu; Jingshan Shi
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

4.  Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties.

Authors:  Giselle de Andrade Ramos; Andressa Souza de Oliveira; Manuela Bartolini; Marina Naldi; Irene Liparulo; Christian Bergamini; Elisa Uliassi; Ling Wu; Paul E Fraser; Monica Abreu; Alessandra Sofia Kiametis; Ricardo Gargano; Edilberto Rocha Silveira; Guilherme D Brand; Lukas Prchal; Ondřej Soukup; Jan Korábečný; Maria Laura Bolognesi; Luiz Antonio Soares Romeiro
Journal:  RSC Med Chem       Date:  2021-05-05

5.  Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor.

Authors:  Viviana Soto-Mercado; Miguel Mendivil-Perez; Marlene Jimenez-Del-Rio; Carlos Velez-Pardo
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 6.  Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.

Authors:  Agnieszka Zagórska; Anna Jaromin
Journal:  Molecules       Date:  2020-07-23       Impact factor: 4.411

7.  Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Authors:  Haizhou Zhu; Venkateshwara Dronamraju; Wei Xie; Swati S More
Journal:  Med Chem Res       Date:  2021-01-15       Impact factor: 1.965

Review 8.  Heterocyclic Compounds: Pharmacology of Pyrazole Analogs From Rational Structural Considerations.

Authors:  Rafael Fernades Costa; Larissa Córdova Turones; Keilah Valéria Naves Cavalcante; Ismael Aureliano Rosa Júnior; Carlos Henrique Xavier; Lucimar Pinheiro Rosseto; Hamilton Barbosa Napolitano; Patrícia Ferreira da Silva Castro; Marcos Luiz Ferreira Neto; Gustavo Mota Galvão; Ricardo Menegatti; Gustavo Rodrigues Pedrino; Elson Alves Costa; José Luis Rodrigues Martins; James Oluwagbamigbe Fajemiroye
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

9.  1,3,5-Triazine Nitrogen Mustards with Different Peptide Group as Innovative Candidates for AChE and BACE1 Inhibitors.

Authors:  Dawid Maliszewski; Agnieszka Wróbel; Beata Kolesińska; Justyna Frączyk; Danuta Drozdowska
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

Review 10.  Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.

Authors:  Teeba Athar; K Al Balushi; Shah Alam Khan
Journal:  Mol Biol Rep       Date:  2021-06-28       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.